PIEL-L Latinoamericana Publicacion periodica en dermatologia | Fundada en 1998
National Institute for Health and Care Excellence (NICE) presenta un resumen de la evidencia al respecto del uso de oxibutinina en pacientes con hiperhidrosis. No se han formulado recomendaciones en base a esta evidencia.
21 March 2017 nice.org.uk/guidance/es10 pat hways
nice.org.uk/guidance/es10
Oxybutynin is an antimuscarinic medicine that can be used to treat hyperhidrosis (excessive sweating); use for this indication is off-label.
This evidence summary includes 4 studies (3 randomised controlled trials [RCTs] and 1 quasirandomised controlled trial) that investigated oxybutynin 2.5 mg to10 mg for treating hyperhidrosis in adults. All the studies compared oxybutynin with placebo and were in non-UK settings. Three studies found that more people treated with oxybutynin reported an improvement in symptoms of hyperhidrosis compared with those treated with placebo; the difference between the groups was statistically significant in all studies. Volume of sweating was measured in the fourth study, which found that the oxybutynin group had statistically significant reductions in sweating from baseline, whereas the placebo group did not. Quality of life was assessed in 3 studies, which found that people treated with oxybutynin reported greater improvements compared with those treated with placebo; all differences between the groups were statistically significant.